32 patients who had antibodies detected (22 Drug+AB+ and 10 Drug-AB+) had a subsequent assay. 12(54.5%) Drug+AB+ and 9(90%) Drug-AB+ patients had persistent drug antibodies on their subsequent test; p=0.11 (Fisher's exact test). Conclusions: IFX and ADA antibodies detected in the presence of drug are associated with lower drug levels, suggesting that such antibodies significantly impact drug pharmacokinetics. Antibodies detected in the presence of drug however are not associated with differences in CRP. Persistence of antibodies over time was evident in a lesser proportion of Drug+AB+ patients vs. Drug-AB+ patients. Whilst this finding failed to reach statistical significance, this may have been due to insufficient patient numbers to adequately power this aspect of our study.
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